MC-Val-Cit-PAB-Retapamulin - CAS 1639793-15-9 Catalog number: BADC-00612

MC-Val-Cit-PAB-Retapamulin is a drug conjugate that combines the antibiotic retapamulin, a potent inhibitor of bacterial protein synthesis, with a peptide linker (MC-Val-Cit-PAB) designed for targeted delivery. Retapamulin is effective against various Gram-positive bacteria, including drug-resistant strains, by binding to the bacterial ribosome and blocking protein elongation. The peptide linker in MC-Val-Cit-PAB-Retapamulin enables selective activation and release of retapamulin at specific target sites, improving its therapeutic efficacy while minimizing side effects associated with systemic drug exposure.

One primary application of MC-Val-Cit-PAB-Retapamulin is in the targeted treatment of bacterial infections, particularly those caused by multidrug-resistant (MDR) pathogens. The peptide linker is designed to be cleaved by enzymes or specific conditions present in the infected tissue, ensuring that retapamulin is released at the site of infection. By directing the drug precisely to the infected area, this approach can enhance the concentration of the antibiotic where it is needed most, reducing the risk of off-target effects and minimizing toxicity to healthy tissues. This makes it a promising candidate for addressing complex infections, including those caused by resistant bacterial strains.

MC-Val-Cit-PAB-Retapamulin also holds potential in the development of novel therapeutic strategies for treating chronic infections, such as those associated with biofilms. Biofilm-forming bacteria are notoriously difficult to treat with conventional antibiotics due to their resistance mechanisms and reduced drug penetration. The targeted release system in MC-Val-Cit-PAB-Retapamulin allows for more efficient delivery to biofilm-associated bacteria, where it can exert its antimicrobial effect directly on the bacterial cells. This targeted approach could lead to more effective treatment of chronic infections in hard-to-reach sites, improving outcomes in patients with persistent bacterial infections.

Additionally, MC-Val-Cit-PAB-Retapamulin can be utilized in the context of personalized medicine. The peptide linker in the conjugate can be tailored to target specific biomarkers or receptors present on the surface of bacterial cells or infected tissues. This level of specificity allows for more precise treatment, offering patients a more individualized approach to combating infections. By customizing the drug delivery system based on patient-specific factors, such as the type of infection or the bacterial strain involved, MC-Val-Cit-PAB-Retapamulin can improve therapeutic outcomes and reduce the risk of adverse effects.

Finally, MC-Val-Cit-PAB-Retapamulin can play a significant role in antibiotic stewardship programs by enabling more effective and targeted antibiotic use. By focusing antibiotic therapy directly on the infection site, the conjugate helps to minimize the overuse of broad-spectrum antibiotics, which is a leading cause of antibiotic resistance. This targeted approach could help preserve the effectiveness of existing antibiotics like retapamulin and reduce the overall burden of resistance, contributing to the global efforts to combat antibiotic resistance and promote more sustainable antibiotic use.